Mucosal immunisation with Clostridium botulinum type C 16 S toxoid and its non-toxic component

Journal of Medical Microbiology

Volumn 51, Issue 10, 2002, Pages 813-820

  Mahmut, Nazira ^a   Inoue, Kaoru ^a   Fujinaga, Yukako ^a   Arimitsu, Hideyuki ^a   Sakaguchi, Yoshihiko ^a   Hughes, Lynn ^a   Hirst, Robert ^a   Murphy, Tom ^a   Tsuji, Takao ^a   Watanabe, Toshihiro ^a   Ohyama, Tohru ^a   Karasawa, Tadahiro ^a   Nakamura, Shinichiro ^a   Yokota, Kenji ^a   Oguma, Keiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTOXIN;

ABSORPTION; ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM BOTULINUM; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; STEM CELL; STRAIN DIFFERENCE; SYNAPTIC TRANSMISSION; WESTERN BLOTTING;

EID: 0036801633     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-51-10-813     Document Type: Article

References (20)

1. Ohyama T, Watanabe T, Fujinaga Y et al. Characterization of nontoxic-nonhemagglutinin component of the two types of progenitor toxin (M and L) produced by Clostridium botulinum Type D CB-16. Microbiol Immunol 1995; 39: 457-465.
2. Fujinaga Y, Inoue K, Shimazaki S et al. Molecular construction of Clostridium botulinum type C progenitor toxin and its gene organization. Biochem Biophys Res Commun 1994; 205: 1291-1298.
3. Fujita R, Fujinaga Y, Inoue K, Nakajima H, Kumon H, Oguma K. Molecular characterization of two forms of nontoxic- nonhemagglutinin components of Clostridium botulinum type A progenitor toxins. FEBS Lett 1995; 376: 41-44.
4. Inoue K, Fujinaga Y, Watanabe T et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64: 1589-1594.
5. Inoue K, Fujinaga Y, Honke K et al. Characterization of haemagglutinin activity of Clostridium botulinum type C and D 16 S toxins, and one subcomponent of haemagglutinin (HA 1). Microbiology 1999; 145: 2533-2542.
6. Oguma K, Syuto B, Iida H, Kubo S. Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains. Infect Immun 1980; 30: 656-660.
7. Oguma K, Fujinaga Y, Inoue K. Clostridium botulinum toxin. J Toxicol Toxin Rev 1997; 16: 253-266.
8. Minton NP. Molecular genetics of clostridial neurotoxins. Curr Top Microbiol Immunol 1995; 195: 161-194.
9. Ohishi I, Sugii S, Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun 1977; 16: 107-109.
10. Ohishi I, Sakaguchi G. Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect Immun 1980; 28: 303-309.
11. Sugii S, Ohishi I, Sakaguchi G. Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect Immun 1977; 17: 491-496.
12. Maksymowych AB, Reinhard M, Malizio CJ, Goodnough MC, Johnson EA, Simpson LL. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect Immun 1999; 67: 4708-4712.
13. Fujinaga Y, Inoue K, Watanabe S et al. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine leading to the efficient absorption of the toxin. Microbiology 1997; 143: 3841-3847.
14. Fujinaga Y, Inoue K, Nomura T et al. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett 2000; 467: 179-183.
15. +-PTX) binds to oligosaccharides containing Ga1β 1-4GIcNAc through one subcomponent of haemagglutinin (HA1). Microbiology 2001; 147: 811-819.
16. Mahmut N, Inoue K, Fujinaga Y et al. Characterization of monoclonal antibodies against haemagglutinin associated with Clostridium botulinum type C neurotoxin. J Med Microbiol 2002; 51: 286-294.
17. Oguma K, Iida H, Inoue K. Observations on nonconverting phage, c-n71, obtained from a nontoxigenic strain of Clostridium botulinum type C. Jpn J Microbiol 1975; 19: 167-172.
18. Oguma K, Iida H, Shiozaki M. Phage conversion to hemagglutinin production in Clostridium botulinum types C and D. Infect Immun 1976; 14: 597-602.
19. Hauser D, Gibert M, Eklund MW, Boquet P, Popoff MR. Comparative analysis of C3 and botulinum neurotoxin genes and their environment in Clostridium botulinum types C and D. J Bacteriol 1993; 175: 7260-7268.
20. Tsuji T, Yokochi T, Kamiya H, Kawamoto Y, Miyama A, Asano Y. Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology 1997; 90: 176-182.